Get started
Author

Michelle Kristine Miller

Observed names: M.K. Miller, Michelle K. Miller, Michelle Miller
OpenAlex ID: A5103809369
Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).
2017 · Gabriel N. Hortobagyi, Salomon M. Stemmer, et al. · Journal of Clinical Oncology · 55
Hydroxyurea Therapy for Pediatric Patients With Hemoglobin SC Disease
2001 · Michelle K. Miller, Sherri A. Zimmerman, et al. · The American journal of pediatric hematology/oncology · 44
Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from MONALEESA-3.
2018 · Dennis J. Slamon, Patrick Neven, et al. · Journal of Clinical Oncology · 24
First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses.
2018 · Gabriel N. Hortobagyi, Shani Paluch-Shimon, et al. · Journal of Clinical Oncology · 20
Abstract P4-10-04: Clinical outcomes of alpelisib in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer by next-generation sequencing-detected PIK3CA alteration status and phosphatase and tensin homolog loss: Biomarker analysis from the SOLAR-1 study
2020 · Dejan Juric, Fabrice Andre, et al. · Cancer Research · 11
Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study.
2022 · Dejan Juric, Hope S. Rugo, et al. · Journal of Clinical Oncology · 8
First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.
2017 · Wolfgang Janni, Howard A. Burris, et al. · Journal of Clinical Oncology · 7
Abstract CT069: Baseline gene expression patterns of CDK4/6 inhibitor-naïve or -refractory HR+, HER2- advanced breast cancer in the phase Ib study of ribociclib plus everolimus plus exemestane
2018 · Aditya Bardia, Shanu Modi, et al. · Cancer Research · 4
309P Antineoplastic (ANP) therapies (Tx) after alpelisib (ALP) or placebo (PBO) + fulvestrant (FUL) in patients (Pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (Mut) advanced breast cancer (ABC): An analysis from SOLAR-1
2021 · F. André, H.S. Rugo, et al. · Annals of Oncology · 1
Erratum to “First-line ribociclib plus letrozole for postmenopausal women with HR+, HER2- ABC: MONALEESA-2 safety results” [Breast 36 (Suppl. 1) (November 2017) S44–S45]
2018 · Wolfgang Janni, Arlene Chan, et al. · The Breast · 1
PDF
EPIK-B6: A phase 2, open-label, 2-part, multicenter study of alpelisib in combination with fulvestrant for men and postmenopausal women with PIK3CA mutation HR–positive, HER2-negative, advanced breast cancer, which progressed on/after aromatase inhibitor treatment in Japan.
2023 · Hiroji Iwata, Naoki Niikura, et al. · Journal of Clinical Oncology
PDF
EPIK-B4: A phase 2, randomized study of metformin (MET) extended release (XR) +/- dapagliflozin (DAPA) to prevent hyperglycemia (HG) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC) treated with alpelisib (ALP) and fulvestrant (FUL).
2022 · William John Gradishar, Azeez Farooki, et al. · Journal of Clinical Oncology
First-Line Ribociclib Plus Letrozole for Postmenopausal Women with HR+, HER2-ABC: Manaleesa-2 Safety Results
2017 · Wolfgang Janni, Arlene Chan, et al. · The Breast
Works count: 13
Citation count: 175
H-index: 7
I10-index: 5
Year
Topic
Type